Skip to main content
S&P 5007,551.81-0.45%DOW51,461.90-1.21%NASDAQ25,978.42-0.01%BTC$76,346.00+0.85%ETH$2,420.07+0.87%GOLD$4,327.00-1.38%OIL$101.32-1.08%
Smart Investors Daily
Biomerica, Inc. logo

NASDAQ · BMRA

Biomerica, Inc.

Healthcare · Medical - Devices

$2.30

Up+$0.07 (+3.04%)

Updated Sep 17, 2026, 1:54 AM

SID Score

3.9/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
7.37M
P/E ratio
-1.86
Dividend yield
0.00%
52-week range
$1.45 – $3.21
Volume
17.5K
Avg. volume
95.23K

Price performance

BMRA price history

1M range · 19 trading sessions · Daily adjusted prices

BMRA closed at $2.30 after 19 trading sessions, up 51.32% for the selected period.

Last close
$2.30
Period change
+51.32%
Period low
$1.52
Period high
$2.36
Daily close
View OHLC price history
BMRA OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 15, 2026$2.36$2.39$2.28$2.3017.5K
Sep 14, 2026$2.26$2.41$2.18$2.3628.22K
Sep 11, 2026$2.25$2.29$2.13$2.2411.94K
Sep 10, 2026$2.1701$2.2456$2.1701$2.2315.37K
Sep 9, 2026$2.35$2.35$1.97$2.26521.41K
Sep 8, 2026$2.27$2.3799$2.205$2.3485.27K
Sep 4, 2026$2.27$2.35$2.21$2.3154.6K
Sep 3, 2026$2.21$2.3305$2.17$2.2258.9K
Sep 2, 2026$2.05$2.20$1.9806$2.2072.82K
Sep 1, 2026$2.11$2.15$1.94$2.0934.37K
Aug 31, 2026$2.15$2.16$2.01$2.0951.13K
Aug 28, 2026$2.13$2.15$2.01$2.14131.88K
Aug 27, 2026$1.71$2.35$1.71$2.103.27M
Aug 26, 2026$1.70$1.7801$1.6899$1.68998.58K
Aug 25, 2026$1.66$1.81$1.66$1.7716.77K
Aug 24, 2026$1.61$1.69$1.601$1.688.47K
Aug 21, 2026$1.575$1.6299$1.575$1.619.98K
Aug 20, 2026$1.5505$1.59$1.52$1.5853.48K
Aug 19, 2026$1.51$1.55$1.50$1.527.53K

Latest BMRA news

The latest Smart Investors Daily articles mentioning BMRA.

Stock researchCompany · Overview

BMRA research

Overview

Company profile and research snapshot.

Company profile

Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. The Company manages its operations as a single operating and reportable segment, which focus on the development, manufacture, marketing, and sale of diagnostic products. The majority of the company's revenue is earned from the Asia, and also has its presence in Europe, North America, Middle East and South America.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
BMRA recent ratings
DateFirmRatingTarget
Oct 19, 2020Aegis CapitalBuy—
Sep 4, 2020Aegis CapitalBuy—
Aug 21, 2020Aegis CapitalBuy—
Dec 17, 2018B. Riley FBRBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 1, 2026

Biomerica Reports Fiscal 2026 Year-End Financial Results

Fiscal 2026 fourth quarter net sales increased approximately 17% compared to the fourth quarter of fiscal 2025Full-year net loss improved by approximately 24% to approximately $3.8 millionInFoods IBS update: 100% of all initial valid claims processed to date have been paid at the full CMS payment rate of $300Research and development expenses decreased 23% as key programs transition toward commercializationSubsequent to fiscal year-end: completed a $2.23 million financing with no warrants or disc

Yahoo · Aug 27, 2026

Biomerica Announces $2.23 Million Financing

Financing priced at $1.60 with no warrants or discountB. Riley Principal Capital and B. Riley executives, as well as Biomerica's CEO and all members of Biomerica’s Board of Directors participated in the financingProceeds expected to strengthen the Company's balance sheet and fund operations and support the Board's ongoing evaluation of potential strategic opportunities, including partnerships and business combinations IRVINE, Calif., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMR

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By